More information

Peter Mirtschink Group

Transcriptional & Metabolic Plasticity in Cardiometabolic Disease

Portrait Peter Mirtschink

Our research centers on how cellular metabolism and gene regulation converge to drive disease progression in non-communicable, chronic inflammatory disease. By integrating advanced transcriptomic and metabolomic approaches, our work examines how immune cells and e.g. cardiomyocytes adapt their energy pathways during stress conditions such as obesity, diabetes, or ischemic injury. Specifically, we explore how hypoxia-inducible factor (HIF-1 and HIF-2) signalling and non-coding RNAs shape transcriptional programs that either exacerbate or mitigate tissue damage. A second major theme is the development and mechanistic study of RNA-based therapies (e.g., antisense oligonucleotides, siRNAs), focusing on their intracellular trafficking and the potential to precisely modulate disease-driving genes. Ultimately, our goal is to leverage these insights to design personalized interventions targeting cellular metabolism—ranging from small-molecule inhibitors and lipid-lowering agents to next-generation RNA therapeutics—that combat pathological remodeling and chronic inflammation.

Peter Mirtschink Research: Figure
Peter Mirtschink Research: Transcriptional & Metabolic Plasticity in Cardiometabolic Disease

Future Projects and Goals

  • Project 1: Immunometabolism & Heart Disease
    • Profiling metabolic changes in cardiac immune cells post-MI and in LP-induced heart failure
    • Investigating HIF isoforms in macrophage vs. neutrophil function and tissue repair
  • Project 2: RNA-Based Therapeutics
    • Developing siRNA and antisense strategies
  • Project: 3 Metabolomics & Precision Medicine
    • High-throughput quantitative metabolomics (NMR & MS) to identify signature “metabotypes”
    • Linking metabolic fingerprints to therapy responsiveness in heart failure, obesity, diabetes, and fatty liver disease
  • Project 4: Hypoxia Signaling as a Druggable Target
    • Exploring HIF1α/HIF2α roles in activated neutrophils/macrophages
    • Evaluating PHD inhibitors for selective immune modulation in ischemic heart conditions
  • Project 4: Regulation of Adipogenesis & Adipocyte Fate by Inflammatory Signalling
    • Collaborative effort (with Chavakis & Wolfrum groups) examining how inflammatory stimuli and/or infection epigenetically reprogram adipocyte progenitors
    • Investigating “inflammatory memory” in adipocyte precursors, which may predispose to obesity and metabolic dysfunction upon future high-caloric challenge
    • Integrating lineage tracing, in vivo infection or LPS models, and state-of-the-art metabolomics to elucidate inflammatory imprinting on adipose tissue development

Methodological and Technical Expertise

  • NMR- and LC-MS–based metabolomics (targeted/untargeted)
  • Transcriptomics (RNA-seq, ChIP), epigenomics (ATAC-Seq), single-cell analyses
  • 7T MRI for metabolic imaging
  • Animal models of chronic inflammatory diseases
  • Primary cell culture (cardiomyocytes, endothelial cells, immune cells, adipocyte progenitors)
  • Advanced metabolic profiling
  • Automated pipelines for NMR and LC-MS
  • Biomarker discovery, patient stratification, therapy monitoring

CV

Since 2023
W2-Professor for Cellular Metabolism and Medical Head, Institute for Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, TU Dresden

2020–2023
Group Leader and Senior Physician, Institute for Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, TU Dresden

2016–2020
Junior Group Leader and Resident Physician, Institute for Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, TU Dresden

2014–2015
Senior researcher, Institute of Molecular Health Sciences (ETH Zurich, Switzerland)

2009–2014
Postdoc, Institute of Molecular Health Sciences (ETH Zurich, Switzerland)

2008–2009
Intern, Department of Internal Medicine, University Clinic Heidelberg

2008
Doctorate degree (Dr. med), Medical Faculty Carl Gustav Carus, TU Dresden

More Information

www.uniklinikum-dresden.de

Selected Publications

Altmann H, Barovic M, Straßburger K, Tschäpel M, Jonas S, Poitz DM, Belavgeni A, Chavakis T, Mirtschink P#, Funk AM#
Validating Centralized Biobanking Workflows for NMR Metabolomics Using the PRIMA Panel
Anal Chem 97(5):2762–2769 doi: 10.1021/acs.analchem.4c04938 (2025)

von Renesse J, von Bechtolsheim F, Jonas S, Seifert L, Alves TC, Seifert AM, Komorek F, Tritchkova G, Menschikowski M, Bork U, Meisterfeld R, Distler M, Chavakis T, Weitz J, Funk AM#, Kahlert C#, Mirtschink P#
Tumour catabolism independent of malnutrition and inflammation in upper GI cancer patients revealed by longitudinal metabolomics
J Cachexia Sarcopenia Muscle 14(1):298–309. doi: 10.1002/jcsm.13131 (2023)

Bischof C*, Mirtschink P*, Yuan T, Wu M, Zhu C, Kaur J, Pham MD, Gonzalez-Gonoggia S, Hammer M, Rogg EM, Sharma R, Bottermann K, Gercken B, Hagag E, Berthonneche C, Sossalla S, Stehr SN, Maxeiner J, Duda MA, Latreille M, Zamboni N, Martelli F, Pedrazzini T, Dimmeler S, Krishnan J
Mitochondrial-cell cycle cross-talk drives endoreplication in heart disease
Sci Transl Med. 13(623):eabi7964. doi: 10.1126/scitranslmed.abi7964 (2021)

Mirtschink P*, Bischof C*, Pham MD, Sharma R, Khadayate S, Rossi G, Fankhauser N, Traub S, Sossalla S, Hagag E, Berthonneche C, Sarre A, Stehr SN, Grote P, Pedrazzini T, Dimmeler S, Krek W, Krishnan J
Inhibition of the Hypoxia-Inducible Factor 1α–Induced Cardiospecific HERNA1 Enhance-Templated RNA Protects From Heart Disease
Circulation 139(24):2778–2792 doi: 10.1161/CIRCULATIONAHA.118.036769 (2019)

Mirtschink P*, Krishnan J*, Grimm F, Sarre A, Hörl M, Kayicki M, Fankhauser N, Christinat Y, Cortijo C, Feehan O, Vukolic A, Sossalla S, Stehr SN, Ule J, Zamboni N, Pedrazzini T and Krek W
HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease
Nature 522(7557):444–449 doi: 10.1038/nature14508 (2015)

*equal first authorship
#equal last authorship